IMS Health and Quintiles' merger takes combined market value to $17.6 billion

4 May 2016

Pharma and health care information and solutions provider IMS Health (NYSE: IMS) is to merge with Quintiles (NYSE: Q), the world’s largest provider of biopharmaceutical development and commercial outsourcing services.

The merged US company is to be called Quintiles IMS Holdings, and promises to provide health care information, technology and services to support clients in the life sciences product lifecycle, from research and development through commercial execution and to patient outcomes.

Based on the closing of IMS Health and Quintiles common stock prices on Monday May 2, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is over $23 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK